Guerbet Showcases Digital Solutions for Diagnostic and Interventional Imaging
Guerbet is highlighting both new and established products in contrast media, injectors, disposables and digital solutions in an interactive Patient Pathway.
The pathway guides attendees through an educational tour and live demonstration of Guerbet's product offerings across the patient experience, beginning with initial examination and diagnosis, moving to treatment with image-guided intervention, and ending with follow-up monitoring technologies.
IBM Watson Imaging Patient Synopsis is a radiologist-
trained AI tool that aims to extract relevant patient
information and summarize it into a tailored and
specific dashboard to help inform diagnostic decisions.
It showcases IBM Watson Imaging Patient Synopsis, a radiologist-trained AI tool that aims to extract relevant patient information and summarizes into a tailored and specific dashboard to help inform diagnostic decisions.
“The AI engine searches for all relevant data in patients’ records and brings in data from unstructured reports to give a more holistic view of the patient,” said Leeann Essai, North American head of marketing. “Now clinicians don’t have to click through an EMR – the system surfaces relevant data so they can make a better decision quickly and efficiently.”
The pathway also includes live demonstrations of Contrast&Care®, a next-level contrast media injection management solution enabling imaging centers to collect, archive, examine and share data directly with Guerbet's injectors to help radiologists with patient care. It also includes demonstrations of Dose&Care®, a state-of-the-art digital solution to monitor patients' exposure to X-rays newly available in the United States.
“We’ve made this dashboard so simple and intuitive. It’s able to give clinicians and physicists the date they know they’ll need for compliance,” said Barry Faigel, western region manager.
The booth also features information on UNIK, an innovative solution tailored for HCPs and decision-makers, to add value at each step of the healthcare journey by interconnecting the comprehensive Guerbet portfolio of contrast media, injection solutions, digital solutions and technical support.
In addition, the company is celebrating the 30th anniversary of OptiRay® (ioversol) injection, a high hydrophilic, low osmolar, non-ionic, monomeric CT contrast medium, and Dotarem® (gadoterate meglumine), Guerbet's macrocyclic and ionic gadolinium-based contrast agent used for MRI procedures. Dotarem® is set to surpass its 100 millionth dose worldwide by the end of this year.